Business Wire

Airship Names Joe Russell Chief Financial Officer

2.8.2023 16:00:00 EEST | Business Wire | Press release

Share

Airship, the mobile app experience company, today announced Joe Russell has joined its executive leadership team as Chief Financial Officer. In this role, Russell will oversee Airship’s finance and business operations and report directly to CEO and president Brett Caine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802538842/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Russell has joined Airship's executive leadership team as Chief Financial Officer to help scale and manage growth as the company unlocks new ways for brands to capture more customer value inside and outside of mobile apps. (Photo: Business Wire)

Russell is a seasoned executive leader with deep expertise in enterprise SaaS. He has led new financial and operational management strategies that accelerated growth while balancing profitability. Russell previously served as CFO of Netbase Quid, an enterprise SaaS provider for data analytics. Prior to that, he held CFO roles at BrightEdge and TalentWave. Russell also worked at Piston Cloud Computing (acquired by Cisco), where he was VP of Finance and Business Operations. Earlier in his career, he led product and sales operations with VMware and Yahoo, and worked as an investment banker at GCA Savvian and Credit Suisse First Boston.

“Joe brings an incredible set of skills and expertise in helping SaaS companies improve operational efficiency, accelerate growth and fuel innovation — making him the perfect match to help execute the next stages of Airship’s expansion,” said Brett Caine, CEO and president, Airship. “For well over a decade, Airship has been first to support game-changing, annual mobile app innovations from Apple and Android, and now we’re redefining what’s possible every day by freeing marketers and product owners to enhance native app experiences without developer support. The no-code era’s impact on value creation, and Airship’s opportunity to unlock it, are massive, and I’m thrilled to have Joe join our team at the helm.”

“Airship has a long history of driving mobile-first innovations that have transformed customer engagement models across industries and redefined how brands create value today,” said Joe Russell, CFO, Airship. “The future is even more exciting. Brands everywhere know the impact mobile apps have on growth and loyalty and their customers do too, but both are often left wanting more. Airship’s unique focus on optimizing the entire mobile app customer lifecycle and empowering a brand’s entire team, are well timed for today’s most pressing needs. I look forward to seizing the opportunity with the team.”

Russell holds an MBA from The Wharton School, an MSc in Accounting and Finance from The London School of Economics and Political Science, and he graduated with a BS in Economics from the University of Washington.

About Airship

No one knows more, does more, or cares more than Airship when it comes to helping brands master mobile app experience (MAX).

From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, no-code native app experience creation and App Store Optimization (ASO).

Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital center of customer experience, brand loyalty and monetization.

With the Airship App Experience Platform and Gummicube’s ASO technology and expertise, brands now have a complete set of solutions to optimize the entire mobile app customer journey – from the point of discovery to loyalty – driving greater value for everyone involved.

For more information, visit www.airship.com, read our blog or follow us on Twitter, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

North America:
Corey Gault
Airship
+1 503-206-9164
corey.gault@airship.com

Kali Myrick
Kali Myrick Communications
+1 503-580-4645
kali@kalimyrick.com

EMEA:
Ana Williams
Airship
+44 (0)20 3405 5160
press@airship.com

Pauline Delorme
Tyto PR
+44 (0)20 3934 8882
Airship@tytopr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 09:30:00 EEST | Press release

Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor

4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis4.8.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the inflammatory mechanisms underlying both symptoms and disease progression in knee osteoarthritis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803530661/en/ 4Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis as a driver of pain and disease progression in knee osteoarthritis INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial conducted across Europe, the United States and Canada

ClickHouse Launches ClickHouse Labs With Andy Pavlo as VP of Database Research3.8.2026 16:30:00 EEST | Press release

ClickHouse today announced the launch of ClickHouse Labs, a new research group led by Andy Pavlo, one of the database industry’s most prominent researchers. Dr. Pavlo joins ClickHouse as Vice President of Database Research and will build a team dedicated to advancing the state of the art in database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803890510/en/ Andy Pavlo, VP of Database Research, ClickHouse Pavlo is an award-winning database researcher and professor at Carnegie Mellon University’s Computer Science Department. He is known throughout the database community for his work on autonomous databases, transaction processing, and large-scale data analytics. At ClickHouse, he will bring that expertise to some of the most ambitious and consequential challenges facing modern data systems, as AI reshapes the demands placed on all data-intensive workloads. “At ClickHouse, we are interested in finding new and inno

Lehman Brothers Treasury Considers Sale and Final Wind-Down3.8.2026 16:30:00 EEST | Press release

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining asset – a $19.6 billion Class 4A allowed claim against Lehman Brothers Holdings Inc. (the “LBHI Claim”). LBT expects the sale to occur, if at all, in August 2026. To the extent the LBHI Claim is sold, LBT expects to make a final distribution to the holders of its existing notes and thereafter facilitate the cancellation of those notes and the final wind down of its estate in September 2026. The foregoing is subject to further consents and authorizations and LBT retains sole discretion to abandon or otherwise discontinue any sale process at any time. Accordingly, there can be no assurances that the sale process will be conducte

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye